

Effect of Folate Targeted Immunotherapy on the Survival of Mice with Lung Tumor Implants




Fig. 1

24JK-FBP Tumor Imaging

FITC Fluorescence






FIG. 2



Con-pe-g.tif



Con-pe-r.tif




Con-pe-l.tif


Untreated



Filc-pe-g.tif



Filc-pe-r.tif



Filc-pe-l.tif

Filcote-FITC
-eated

Fig. 3

↑
FITC images

↑
PF images

↑
Transmitted

Tumor Growth Curve*




FIG. 4

Effect of Cytokine Combinations on Folate-Targeted Immunotherapy*




Fig. 5

Downloaded from www.jco.org

Immunotherapy Update*




FIG. 6

Synergistic Effect of FEFITC and IL-2 in Folate-Targeted Immunotherapy




Fig. 7

The Effect of Mouse NK Cell Depletion on Folate Targeted Immunotherapy*




Fig. 8

Development of Cellular Immunity against the Parental M109 Tumor Cells




Fig. 9

-o- FEFITC (1500 nmol/kg), IL-2 (250,000 IU/day), and IFN- α (25,000 U/day)

-▲-▼-◆- PBS control groups at respective tumor implantation time points

**FEFITC-Targeted Immunotherapy:
the IL-2 dosing effect on i.p. M109 Tumor**




Fig. 10

IFN- α Further Enhances IL-2-augmented Immunotherapeutic Effect of FEFITC in Mice with Pre-existing Anti-FITC Antibody




Fig. 11

Effect of Depletion of CD8⁺ T cells on Folate-Targeted Immunotherapy




Fig. 12

The Effect of a Third Cytokine, GM-CSF on Folate-Targeted Immunotherapy

M109 Lung Carcinoma




Fig. 13

FEFITC-Targeted Immunotherapy: the IFN- α dosing effect on i.p. M109 Tumor





Fig. 14

[illegible]

Synergistic Effect of FEFITC and IFN- α against Intraperitoneal M109 Tumor




Fig. 16

**Folate-DNP Further Enhanced the Therapeutic Effect of
a High Dose Combination of IL-2 and IFN- α in Mice
with Pre-existing Anti-DNP Antibody**




Fig. 17